<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="111729">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01649427</url>
  </required_header>
  <id_info>
    <org_study_id>CERL080ADE27</org_study_id>
    <nct_id>NCT01649427</nct_id>
  </id_info>
  <brief_title>Comparison of a Tacrolimus Hexal® Based Regimen Versus a Prograf® Based Regimen in de Novo Renal Transplant Recipients</brief_title>
  <acronym>Spartacus</acronym>
  <official_title>Multi-center, Open-label, Prospective, Randomized, Parallel Group Study Investigating a Tacrolimus Hexal® Based Regimen Versus a Prograf® Based Regimen in de Novo Renal Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate if Tacrolimus Hexal® has similar pharmacokinetic
      properties compared to Prograf® in de novo renal transplant patients and whether the
      comparable exposure results in similar renal function.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>measured by dose normalized AUC 0-12 h</measure>
    <time_frame>During the first month</time_frame>
    <description>PHASE I: To demonstrate that the pharmacokinetics of Tacrolimus Hexal® assessed by the ratio of the AUC0-12h over a one month period post-transplantation is comparable to Prograf® in renal transplant patients.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of GFR over time and between the two groups</measure>
    <time_frame>at Baseline and month 6</time_frame>
    <description>PHASE II To demonstrate non-inferiority in renal function measured by glomerular filtration rate GFR(Nankivell formula) between both treatment arms at month 6 post-transplantation in renal transplant patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of BPAR, graft loss or death</measure>
    <time_frame>12 month</time_frame>
    <description>safety and tolreability during 12 month</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">76</enrollment>
  <condition>Pharmacokinetics Study in de Novo Kidney Transplantation</condition>
  <arm_group>
    <arm_group_label>PHASE I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In a first phase of the study, pharmacokinetic parameters will be evaluated with a total of 60 evaluable patients (30 patients per treatment group).One Group on Prograf, the other on Tacrolimus Hexal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prograf</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After initial Phase 1 Phase two follows until month 12. Group 1 up to 163 pts. on Prograf</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tacroliums Hexal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After initial Phase 1 Phase two follows until month 12. Group 2 up to 163 pts. on Tacrolimus Hexal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Immunosupressive Drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simulect</intervention_name>
    <description>Induction Therapy: 2x20mg; day 0 and day 4 post Tx</description>
    <arm_group_label>PHASE I</arm_group_label>
    <arm_group_label>Immunosupressive Drug</arm_group_label>
    <other_name>Basiliximab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Steroids</intervention_name>
    <description>recommended on Day 14 after transplantation steroid dose is reduced to 5 mg prednisolon or eqivalent. A minimum dose of 5 mg prednisolon or equivalent should be continued until Month 6.</description>
    <arm_group_label>PHASE I</arm_group_label>
    <arm_group_label>Prograf</arm_group_label>
    <arm_group_label>Tacroliums Hexal</arm_group_label>
    <other_name>prednisolon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prograf</intervention_name>
    <description>0.15 mg/KG Transplantation to Month 1: 8 - 12 ng/ml Month 1 to Month 3: 5 - 10 ng/ml Month 3 to Month 6: 5 - 8 ng/ml</description>
    <arm_group_label>PHASE I</arm_group_label>
    <arm_group_label>Prograf</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus Hexal</intervention_name>
    <description>0.15 mg-Kg Transplantation to Month 1: 8 - 12 ng/ml Month 1 to Month 3: 5 - 10 ng/ml Month 3 to Month 6: 5 - 8 ng/ml</description>
    <arm_group_label>Tacroliums Hexal</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion:

        primary or sec. kidney transplanted patiens, written consent, cold ischemia &lt; 24 h

        Exclusion:

        multi organ, immunological risc pts., PRA &gt;20%, Antibodys against HLA-type of donor organ,
        hypersensitivity against Tacro or MMF,

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>10098</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bochum</city>
        <zip>44892</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Duesseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kaiserslautern</city>
        <zip>67655</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Koeln-Merheim</city>
        <zip>51109</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <lastchanged_date>October 23, 2015</lastchanged_date>
  <firstreceived_date>July 20, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetics Study</keyword>
  <keyword>Tacroliums</keyword>
  <keyword>GFR</keyword>
  <keyword>kdney</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Basiliximab</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
